Ubs Asset Management Americas Inc Xenon Pharmaceuticals Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 162,466 shares of XENE stock, worth $6.56 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
162,466
Previous 77,484
109.68%
Holding current value
$6.56 Million
Previous $3.34 Million
89.93%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding XENE
# of Institutions
221Shares Held
69.6MCall Options Held
59.7KPut Options Held
60.7K-
Avoro Capital Advisors LLC New York, NY5.67MShares$229 Million3.02% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.42MShares$178 Million1.86% of portfolio
-
Wellington Management Group LLP Boston, MA3.83MShares$155 Million0.03% of portfolio
-
Commodore Capital LP New York, NY2.75MShares$111 Million9.63% of portfolio
-
Capital World Investors Los Angeles, CA2.68MShares$108 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.51B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...